8-K: BioCardia Raises $1.85 Million Through At-The-Market Stock Sales

BioCardia, Inc. sold 335,112 shares of common stock for gross proceeds of approximately $1.85 million between April 1, 2024 and June 10, 2024.

Summary

• BioCardia, Inc. sold 335,112 shares of its common stock between April 1, 2024, and June 10, 2024.
• The sales were conducted at then-market prices.
• The total gross proceeds from these sales amounted to approximately $1.85 million.
• These sales were made under the company's previously disclosed At The Market Offering Agreement.
• Following these sales, BioCardia has the capacity to issue up to an additional $264,000 of shares under the existing prospectus supplement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as the company successfully raised capital, but the amount is relatively small and the remaining capacity is limited.

Positives

• BioCardia successfully raised $1.85 million through the sale of common stock.
• The company still has the ability to raise additional capital through its existing At The Market Offering Agreement.

Risks

• The company's ability to raise additional capital is limited to $264,000 under the current agreement.
• The company's liquidity position should be reviewed in the most recent Quarterly Report on Form 10-Q.

Future Outlook

The company may continue to utilize its At The Market Offering Agreement to raise additional capital, up to the remaining capacity of $264,000.

Management Comments

• Peter Altman, Ph.D., President and Chief Executive Officer, signed the report on behalf of BioCardia, Inc.

Industry Context

The use of At The Market offerings is a common method for small to mid-cap companies to raise capital, particularly in the biotech sector, allowing them to access funds without the need for large, dilutive offerings.

Comparison to Industry Standards

• Many small biotech companies use At-The-Market (ATM) offerings to raise capital incrementally.
• The amount raised, $1.85 million, is relatively small compared to larger capital raises in the biotech industry, but is typical for companies of BioCardia's size and stage.
• Comparable companies might include other clinical-stage biotech firms that utilize ATM offerings to fund ongoing research and development.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The capital raise provides the company with additional funding for operations and development.

Next Steps

• BioCardia may continue to sell shares under the At The Market Offering Agreement up to the remaining capacity.
• Investors should monitor the company's future filings for updates on its financial position and capital raising activities.

Key Dates

Keywords

At The Market Offering, common stock, capital raise, equity financing, BioCardia, BCDA